CUAMC
China Universal Asset Management Company Portfolio holdings
AUM
$1.06B
1-Year Return
31.81%
This Quarter Return
-1.39%
1 Year Return
+31.81%
3 Year Return
+205.04%
5 Year Return
–
10 Year Return
–
AUM
$345M
AUM Growth
+$21M
(+6.5%)
Cap. Flow
+$33M
Cap. Flow
% of AUM
9.58%
Top 10 Holdings %
Top 10 Hldgs %
32.78%
Holding
466
New
14
Increased
365
Reduced
39
Closed
20
Top Buys
| 1 |
Amazon
AMZN
|
$3.98M |
| 2 |
Procter & Gamble
PG
|
$3.03M |
| 3 |
Booking.com
BKNG
|
$2.86M |
| 4 |
Apple
AAPL
|
$2.77M |
| 5 |
SPDR Gold MiniShares Trust
GLDM
|
$2.63M |
Top Sells
| 1 |
NVIDIA
NVDA
|
$3.25M |
| 2 |
TSMC
TSM
|
$3.11M |
| 3 |
Carnival Corp
CCL
|
$2.64M |
| 4 |
On Holding
ONON
|
$2.57M |
| 5 |
Advanced Micro Devices
AMD
|
$2.07M |
Sector Composition
| 1 | Technology | 38.24% |
| 2 | Consumer Discretionary | 20.57% |
| 3 | Healthcare | 19.52% |
| 4 | Communication Services | 8.19% |
| 5 | Consumer Staples | 3.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
301
Sana Biotechnology
SANA
$752M
| $19.5K | 0.01% |
5,047
+2,537
| +101% | +$9.82K |
|
302
Regenxbio
RGNX
$490M
| $18.5K | 0.01% |
1,125
+555
| +97% | +$9.14K |
|
303
Repligen
RGEN
$7.01B
| $18.3K | 0.01% |
115
| – | – |
|
304
Edwards Lifesciences
EW
$47.5B
| $17.7K | 0.01% |
256
| – | – |
|
305
Novavax
NVAX
$1.28B
| $17.6K | 0.01% |
2,424
+1,293
| +114% | +$9.36K |
|
306
Arcturus Therapeutics
ARCT
$485M
| $17.5K | 0.01% |
683
+335
| +96% | +$8.56K |
|
307
Charles River Laboratories
CRL
$8.07B
| $17.4K | 0.01% |
89
| – | – |
|
308
Kura Oncology
KURA
$713M
| $17.3K | 0.01% |
1,898
+1,001
| +112% | +$9.13K |
|
309
Travere Therapeutics
TVTX
$1.93B
| $17.1K | 0.01% |
1,917
+939
| +96% | +$8.4K |
|
310
Galapagos
GLPG
$2.2B
| $17.1K | 0.01% |
495
+265
| +115% | +$9.16K |
|
311
IQVIA
IQV
$31.9B
| $16.5K | ﹤0.01% |
84
| – | – |
|
312
Editas Medicine
EDIT
$248M
| $16.3K | ﹤0.01% |
2,095
+1,190
| +131% | +$9.28K |
|
|
FTCH
313
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $16.3K | ﹤0.01% |
7,800
| – | – |
|
314
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $15.8K | ﹤0.01% |
911
+453
| +99% | +$7.87K |
|
315
Phathom Pharmaceuticals
PHAT
$875M
| $15.1K | ﹤0.01% |
1,455
+738
| +103% | +$7.65K |
|
316
RAPT Therapeutics
RAPT
$214M
| $14.8K | ﹤0.01% |
111
+55
| +98% | +$7.32K |
|
317
Exact Sciences
EXAS
$10.2B
| $14.7K | ﹤0.01% |
216
-6,941
| -97% | -$474K |
|
|
PETQ
318
DELISTED
PetIQ, Inc. Class A Common Stock
PETQ
| $14.7K | ﹤0.01% |
747
+365
| +96% | +$7.19K |
|
319
Tarsus Pharmaceuticals
TARS
$2.43B
| $14.7K | ﹤0.01% |
828
+476
| +135% | +$8.46K |
|
320
Wave Life Sciences
WVE
$1.32B
| $14.6K | ﹤0.01% |
2,536
+1,247
| +97% | +$7.17K |
|
|
ALPN
321
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $14.5K | ﹤0.01% |
1,269
+640
| +102% | +$7.33K |
|
322
Dyne Therapeutics
DYN
$2.02B
| $14K | ﹤0.01% |
1,558
+794
| +104% | +$7.11K |
|
323
Alector
ALEC
$305M
| $13.9K | ﹤0.01% |
2,149
+1,056
| +97% | +$6.84K |
|
324
Anavex Life Sciences
AVXL
$807M
| $13.8K | ﹤0.01% |
2,103
+1,044
| +99% | +$6.84K |
|
325
4D Molecular Therapeutics
FDMT
$340M
| $13.7K | ﹤0.01% |
1,078
+529
| +96% | +$6.73K |
|